Market and Product Forecasts: Asthma – Premium products to offset loss to generics

Published by: Datamonitor

Published: Sep. 7, 2012 - 73 Pages

Table of Contents

Market and Product Forecasts: Asthma – Premium products to offset loss to generics

OVERVIEW

Catalyst

Summary

EXECUTIVE SUMMARY

Strategic scoping and focus

Datamonitor key findings

METHODOLOGY AND MARKET DEFINITION

Market definition for asthma

Long-acting beta 2 agonists + inhaled corticosteroids (R3F1)

Long-acting beta 2 agonists (R3A3)

Short-acting beta 2 agonists (R3A4)

Inhaled corticosteroids (R3D1)

Antileukotrienes (R3J2)

All other asthma and chronic obstructive pulmonary disease (R3X2)

Forecast methodology and assumptions

Methodology flow

Patent expiries

New product launches

MARKET OVERVIEW AND CONTEXT

Current and future market dynamics overview

Generic erosion to cause short-term market decline

ICS/LABAs to maintain dominance despite in-class changes

Marginal growth forecast for the US market

The Japanese asthma market faces a turbulent 10 years

Asthma markets to stagnate in the EU

France

Germany

Italy

Spain

UK

BRAND FORECASTS

Advair (fluticasone/salmeterol; GlaxoSmithKline)

Forecast assumptions

Advair forecast 2012–21

Singulair (montelukast; Merck & Co.)

Forecast assumptions

Singulair forecast 2012–21

Symbicort (budesonide/formoterol; AstraZeneca)

Forecast assumptions

Symbicort forecast 2012–21

Dulera (mometasone/formoterol; Merck & Co.)

Forecast assumptions

Dulera forecast 2012–21

Xolair (omalizumab; Genentech/Roche/Novartis)

Forecast assumptions

Xolair forecast 2012–21

Flutiform (fluticasone/formoterol; SkyePharma)

Forecast assumptions

Flutiform forecast 2012–21

Relovair (Breo/Relvar, fluticasone furoate/vilanterol; GlaxoSmithKline)

Forecast assumptions

Relovair forecast 2012–21

QMF149 (mometasone/indacaterol; Novartis)

Forecast assumptions

QMF149 forecast 2012–21

Lebrikizumab (Genentech/Roche)

Forecast assumptions

Lebrikizumab forecast 2012–21

BIBLIOGRAPHY

Websites

Datamonitor reports

APPENDIX

Contributing experts

Forecast methodology

Volume and value forecast methodology

Physician sample breakdown

TABLES

Table: Price sources and calculations, by country, 2012

Table: Exchange rates used for calculating prices, 2012

Table: Patent expiry dates for key marketed brands in asthma, by country, 2012

Table: Launch dates for asthma pipeline products, 2012–21

Table: Asthma brand sales in the seven major markets ($m), 2012–21

Table: Datamonitor’s price assumptions for Advair, 2012

Table: Advair (fluticasone/salmeterol; GlaxoSmithKline) forecast sales for asthma in the seven major markets, by device ($m), 2012–21

Table: Datamonitor’s price assumptions for Singulair, 2012

Table: Singulair (montelukast; Merck & Co.) forecast sales for asthma in the seven major markets ($m), 2012–21

Table: Datamonitor’s price assumptions for Symbicort

Table: Symbicort (budesonide/formoterol; AstraZeneca) forecast sales for asthma in the seven major markets ($m), by device, 2012–21

Table: Datamonitor’s price assumptions for Dulera, 2012

Table: Dulera (mometasone/formoterol; Merck & Co.) forecast sales for asthma in the US ($m), 2012–21

Table: Datamonitor’s price assumptions for Xolair, 2012

Table: Xolair (omalizumab; Genentech/Roche) forecast sales for asthma in the seven major markets ($m), 2012–21

Table: Flutiform (fluticasone/formoterol; SkyePharma) forecast sales for asthma in Japan and the five major EU markets ($m), 2012–21

Table: Relovair (fluticasone furoate/vilanterol; GlaxoSmithKline) forecast sales for asthma in the seven major markets ($m), 2012–21

Table: QMF149 (mometasone/indacaterol; Novartis) forecast sales for asthma in Japan and the five major EU markets ($m), 2012–21

Table: Lebrikizumab (Genentech/Roche) forecast sales for asthma in the US and the five major EU markets ($m), 2012–21

Table: Pulmonologist sample breakdown, 2012

FIGURES

Figure: Patient-based forecast methodology for asthma, 2012

Figure: Asthma sales in the seven major markets, by country ($bn), 2012–21

Figure: Timeline: forecast launch dates for asthma, 2012–21

Figure: Asthma sales in the seven major markets, by product type ($bn), 2012–21

Figure: Asthma sales in the seven major markets, by class ($bn), 2012–21

Figure: Asthma market value in the US ($bn), 2012–21

Figure: Asthma market value in Japan ($m), 2012–21

Figure: Asthma market value in France ($m), 2012–21

Figure: Asthma market value in Germany ($m), 2012–21

Figure: Asthma market value in Italy ($m), 2012–21

Figure: Asthma market value in Spain ($m), 2012–21

Figure: Asthma market value in the UK ($m), 2012–21

Figure: Advair (fluticasone/salmeterol; GlaxoSmithKline) and generic forecast sales for asthma in the seven major markets, by device ($m), 2012–21

Figure: Advair (fluticasone/salmeterol; GlaxoSmithKline) forecast sales for asthma in the seven major markets, ($bn), 2012–21

Figure: Singulair (montelukast; Merck & Co.) forecast sales for asthma in the seven major markets ($bn), 2012–21

Figure: Symbicort (budesonide/formoterol; AstraZeneca) forecast sales for asthma in the seven major markets ($bn), 2012–21

Figure: Dulera (mometasone/formoterol; Merck & Co.) forecast sales for asthma in the US ($m), 2012–21

Figure: Xolair (omalizumab; Genentech/Roche) forecast sales for asthma in the seven major markets ($bn), 2012–21

Figure: Flutiform (fluticasone/formoterol; SkyePharma) forecast sales for asthma in Japan and the five major EU markets ($m), 2012–21

Figure: Relovair (fluticasone furoate/vilanterol; GlaxoSmithKline) forecast sales for asthma in the seven major markets ($bn), 2012–21

Figure: QMF149 (mometasone/indacaterol; Novartis) forecast sales for asthma in Japan and the five major EU markets ($m), 2012–21

Figure: Lebrikizumab (Genentech/Roche) forecast sales for asthma in the US and the five major EU markets ($m), 2012–21

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.